MSE
ENTA icon

MUFG Securities EMEA’s Enanta Pharmaceuticals ENTA Stock Holding History

MUFG Securities EMEA’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-26,400
Closed -$2.23M – 369
2019
Q2 		$2.23M Buy
+26,400
New +$2.37M 0.02% 258

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

MUFG Securities EMEA's ENTA Position: Q3 2019 in Review

MUFG Securities EMEA sold out of Enanta Pharmaceuticals (ENTA) in Q3 2019, closing a stake of 26,400 shares — an estimated $2.23M sold.

MUFG Securities EMEA first reported a position in ENTA in Q2 2019 and held it in 1 quarter. The position peaked at $2.23M in Q2 2019. 176 funds tracked by Wall St. Rank hold ENTA as of Q3 2019.

  • MUFG Securities EMEA reported no remaining Enanta Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • MUFG Securities EMEA sold 26,400 Enanta Pharmaceuticals shares in Q3 2019, an estimated $2.23M.
  • MUFG Securities EMEA first reported a position in Enanta Pharmaceuticals in Q2 2019 and held it in 1 quarter.
  • MUFG Securities EMEA's Enanta Pharmaceuticals position peaked at $2.23M in Q2 2019.
  • 176 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2019.

Based on MUFG Securities EMEA's 13F filing for Q3 2019, filed 12 Nov 2019.